CYB003

CYB003 is a proprietary, deuterated analogue of psilocin (the active metabolite of psilocybin), developed as a new chemical entity for the adjunctive treatment of major depressive disorder (MDD). It is designed to provide the therapeutic benefits of classical psychedelics while addressing limitations such as variable pharmacokinetics and lengthy duration. As a tryptamine derivative, CYB003 acts primarily as an agonist at the serotonin 5-HT2A receptor, producing psychedelic-like effects. The molecule’s deuteration improves its pharmacokinetic profile by reducing variability in circulating levels, enabling faster onset and shorter duration compared to traditional psilocybin or psilocin. Clinical data show rapid, robust, and durable antidepressant effects with high rates of remission after one or two oral doses. The drug has received FDA Breakthrough Therapy Designation for MDD and is currently in phase 3 clinical trials[1][2][3][4][5][6][7].

Other names

deuterated psilocindeuterated psilocybin analogue